Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823897 | 0.98 | KMT2A (0.58) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| Hydrochloric Acid SCHEMBL28136330 | 0.98 | KMT2A (0.58) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL3496093 | 0.89 | KMT2A (0.58) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL31254284 | 0.89 | KMT2A (0.58) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL6827755 | 0.87 | KMT2A (0.57) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL30866830 | 0.84 | TSHR (0.59) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL5261945 | 0.84 | TSHR (0.59) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL13311778 | 0.82 | KMT2A (0.60) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL29595267 | 0.82 | L3MBTL1 (0.60) | KMT2AMEN1TSHRL3MBTL1AKR1C3 | |
| SCHEMBL1134878 | 0.82 | TSHR (0.57) | KMT2AMEN1TSHRL3MBTL1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2019201283-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| US-8530137-B2 | Photoresist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20110200935-A1 | PHOTORESIST COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200935-A1 | PHOTORESIST COMPOSITION | C1R, F12, C1S | KMT2A 2752/4885MEN1 2992/4885TSHR 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.